Chemomab Therapeutics (CMMB) Cash from Financing Activities (2017 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Cash from Financing Activities came in at $2.1 million in Q4 2023, up 345.45% YoY from $478836.7 in Q4 2022, and up 71000.0% on a QoQ basis from $3000.0 in Q3 2023.
Chemomab Therapeutics (CMMB) Cash from Financing Activities (2017 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Cash from Financing Activities data on file, last reported at $2.1 million in Q4 2023.
- Quarterly Cash from Financing Activities rose 345.45% year-over-year to $2.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.5 million (up 533.66% YoY) and the FY2025 annual result came in at $7.2 million, down 27.47% from the prior year.
- Cash from Financing Activities rose to $2.1 million in Q4 2023, from $3000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $47.8 million in Q1 2021 to a low of -$1.2 million in Q2 2019.
- A 5-year average of $5.9 million and a median of $531000.0 in 2020 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities surged 9459.8% — and 2022, when it slumped 972.84%.
- Tracing CMMB's Cash from Financing Activities over 5 years: stood at -$1.2 million in 2019, then jumped by 146.99% to $563000.0 in 2020, then sank by 114.39% to -$81000.0 in 2021, then tumbled by 972.84% to -$869000.0 in 2022, then soared by 345.45% to $2.1 million in 2023.
- The last three Cash from Financing Activities figures came in at $2.1 million (Q4 2023), $3000.0 (Q3 2023), and $1.4 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Chemomab Therapeutics | 13.62 Mn | 3.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.13 Mn |
| Dec 31, 2023 | 2.13 Mn |
| Sep 30, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Dec 31, 2022 | -869,000.00 |
| Dec 31, 2022 | -869,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Jun 30, 2022 | 22,000.00 |
| Dec 31, 2021 | -81,000.00 |
| Dec 31, 2021 | -81,000.00 |
| Sep 30, 2021 | -72,000.00 |
| Sep 30, 2021 | -72,000.00 |
| Jun 30, 2021 | 13.43 Mn |
| Jun 30, 2021 | 13.43 Mn |
| Mar 31, 2021 | 47.80 Mn |
| Mar 31, 2021 | 47.80 Mn |